1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com

Contact:
Zachary A. Nagle, Investor Relations — 201-847-5453
Colleen T. White, Corporate Communications — 201-847-5369

BD ANNOUNCES RESULTS FOR 2011 FIRST FISCAL QUARTER

	•		Reports diluted earnings per share from continuing operations of $1.35, including approximately $0.07 related to the timing of certain tax benefits. These benefits were included in the Company’s full year guidance provided on its 2010 year-end earnings conference call.
	•		Reports revenues of $1.842 billion, a decrease of 1.4 percent year-over-year.
	•		Reaffirms full fiscal year 2011 guidance of reported revenues and EPS to increase about 4 percent and between 11 percent and 13 percent, respectively.

Franklin Lakes, NJ (February 7, 2011) — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.842 billion for the first fiscal quarter ended December 31, 2010, representing a decrease of 1.4 percent from the prior-year period. On a foreign currency-neutral basis, revenue decreased 1.5 percent. The revenue decline reflects an unfavorable comparison to the prior year of about 4 percentage points due to strong sales related to the pandemic flu and U.S. stimulus revenues in fiscal 2010.

The Company also repurchased $837 million of its common stock during the quarter. BD continues to plan aggregate share repurchases of $1.5 billion in fiscal 2011 and an additional $600 million in fiscal 2012.

“We are pleased with our performance in the first fiscal quarter given the challenging environment,” said Edward J. Ludwig, Chairman and Chief Executive Officer. “While revenue came in slightly below our expectations, our discipline around operational excellence enabled us to deliver earnings per share in line with our previous guidance. We continued to return significant value to shareholders, while also investing in geographic expansion, new product platforms and operational excellence programs.”

First Quarter Earnings
Reported diluted earnings per share for the first quarter were $1.35, compared with $1.25 in the prior-year period, representing an 8.0 percent increase. On a foreign currency-neutral basis, diluted earnings per share for the first quarter increased by 4.8 percent.

For the quarter, reported diluted earnings per share from continuing operations included an approximate $0.07 favorable impact due to the timing of certain tax benefits. These benefits, which were reflected in our previous full year guidance, resulted from certain first quarter events, including the retroactive extension of the U.S. research tax credit.

Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $927 million, representing a decrease of 4.5 percent compared with the prior-year period, or a decrease of 4.3 percent on a foreign currency-neutral basis. The segment’s revenue decline reflects an unfavorable comparison to the prior year of about 6 percentage points due to strong sales related to the H1N1 flu pandemic in fiscal year 2010, partially offset by solid growth in the Diabetes Care unit with particularly strong growth in pen needles.

In the BD Diagnostics segment, worldwide revenues for the quarter were $602 million, representing an increase of 1.0 percent compared with the prior-year period, or 0.6 percent on a foreign currency-neutral basis. Segment revenue growth was negatively impacted by about 2 percentage points due to strong sales related to the flu pandemic in fiscal year 2010. The segment growth was primarily driven by strong sales in Preanalytical Systems safety-engineered products, and Women’s Health and Cancer in the Diagnostic Systems unit.

In the BD Biosciences segment, worldwide revenues for the quarter were $314 million, representing an increase of 3.7 percent compared with the prior-year period, or 3.5 percent on a foreign currency-neutral basis. Segment revenue growth was negatively impacted by about 2 percentage points due to strong sales related to stimulus spending in the U.S. in fiscal year 2010. Segment growth was primarily driven by instrument and reagent sales in the Cell Analysis unit.

Geographic Results
First quarter revenues in the U.S. were $829 million, representing a decrease of 2.9 percent compared with the prior-year period, including a negative impact of 6.0 percentage points due to flu pandemic-related sales in fiscal year 2010. Revenues outside of the U.S. were $1.013 billion, representing a decrease of 0.2 percent compared with the prior-year period, or a decrease of 0.3 percent on a foreign currency-neutral basis. International revenue growth was negatively impacted by about 3 percentage points related to the flu pandemic in fiscal year 2010. Revenues reflected continued strength in emerging markets, which was partially offset by a decline in sales in Europe.

Company Reaffirms Previously Communicated Fiscal Year 2011 Guidance
The Company continues to estimate that reported revenues for the full fiscal year 2011 will increase about 4 percent compared to fiscal year 2010. The Company also continues to expect reported diluted earnings per share from continuing operations for fiscal year 2011 to be between $5.45 and $5.55, an increase of approximately 11 to 13 percent over fiscal year 2010. Diluted earnings per share from

continuing operations for fiscal year 2011 are expected to increase 10 to 12 percent over adjusted diluted earnings per share from continuing operations, excluding specified item, of $4.94 for fiscal year 2010. The specified item represents a 2010 non-cash charge of $0.04 cents per share related to healthcare reform impacting Medicare Part D reimbursements.

Conference Call Information
A conference call regarding BD’s first quarter results and its expectations for the full fiscal year 2011 will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 10:00 a.m. (ET) Tuesday, February 8, 2011. The related slides are available concurrent with this press release at www.bd.com/investors. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 1-800-642-1687 (domestic) and 1-706-645-9291 (international) through the close of business on Tuesday, February 15, 2011, access code 37117544.

Non-GAAP Financial Measures
This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables and the Form 8-K that BD filed today with the SEC.

About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

***

This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues and earnings per share. Forward-looking statements may be identified by the use of words such as “expect”, “estimate” or words of similar meaning in conjunction with statements of our future performance. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: the unknown consequences of the recently-enacted healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our ability to access credit markets and finance our operations, the demand for

our products and services, or our suppliers’ ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; our ability to successfully integrate any businesses we acquire; and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

		Three Months Ended December 31,
		2010				2009				% Change
REVENUES		$	1,842,005			$	1,868,818				(1.4	)
Cost of products sold			865,431				894,324				(3.2	)
Selling and administrative			447,954				445,673				0.5
Research and development			115,542				99,151				16.5
TOTAL OPERATING COSTS AND EXPENSES			1,428,927				1,439,148				(0.7	)
OPERATING INCOME			413,078				429,670				(3.9	)
Interest income			15,222				8,789				73.2
Interest expense			(15,553	)			(12,987	)			19.8
Other expense, net			(4,596	)			(2,354	)			95.2
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES			408,151				423,118				(3.5	)
Income tax provision			93,875				119,025				(21.1	)
INCOME FROM CONTINUING OPERATIONS			314,276				304,093				3.3
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF $223 AND $4,617, RESPECTIVELY			1,661				12,283			NM
NET INCOME		$	315,937			$	316,376				(0.1	)
EARNINGS PER SHARE
Basic:
Income from continuing operations		$	1.38			$	1.28				7.8
Income from discontinued operations		$	0.01			$	0.05				(80.0	)
Net income		$	1.39			$	1.33				4.5
Diluted:
Income from continuing operations		$	1.35			$	1.25				8.0
Income from discontinued operations		$	0.01			$	0.05				(80.0	)
Net income		$	1.36			$	1.30				4.6
AVERAGE SHARES OUTSTANDING
Basic			228,083				237,360
Diluted			232,915				242,965

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

		Three Months Ended December 31,
		2010				2009				% Change
BD MEDICAL
United States		$	405,527			$	432,576				(6.3	)
International			521,020				538,096				(3.2	)
TOTAL		$	926,547			$	970,672				(4.5	)
BD DIAGNOSTICS
United States		$	308,851			$	310,205				(0.4	)
International			292,871				285,269				2.7
TOTAL		$	601,722			$	595,474				1.0
BD BIOSCIENCES
United States		$	114,224			$	110,636				3.2
International			199,512				192,036				3.9
TOTAL		$	313,736			$	302,672				3.7
TOTAL REVENUES
United States		$	828,602			$	853,417				(2.9	)
International			1,013,403				1,015,401				(0.2	)
TOTAL		$	1,842,005			$	1,868,818				(1.4	)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended December 31,
(Unaudited; Amounts in thousands)

		United States
		2010				2009				% Change
BD MEDICAL
Medical Surgical Systems		$	254,254			$	273,991				(7.2	)
Diabetes Care			99,585				96,564				3.1
Pharmaceutical Systems			51,688				62,021				(16.7	)
TOTAL		$	405,527			$	432,576				(6.3	)
BD DIAGNOSTICS
Preanalytical Systems		$	162,059			$	156,236				3.7
Diagnostic Systems			146,792				153,969				(4.7	)
TOTAL		$	308,851			$	310,205				(0.4	)
BD BIOSCIENCES
Cell Analysis		$	80,255			$	77,604				3.4
Discovery Labware			33,969				33,032				2.8
TOTAL		$	114,224			$	110,636				3.2
TOTAL UNITED STATES		$	828,602			$	853,417				(2.9	)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended December 31, (continued)
(Unaudited; Amounts in thousands)

		International
										% Change
		2010				2009				Reported				FXN				FX Impact
BD MEDICAL
Medical Surgical Systems		$	258,474			$	259,186				(0.3	)			(2.2	)			1.9
Diabetes Care			114,297				104,957				8.9				8.8				0.1
Pharmaceutical Systems			148,249				173,953				(14.8	)			(10.9	)			(3.9	)
TOTAL		$	521,020			$	538,096				(3.2	)			(2.8	)			(0.4	)
BD DIAGNOSTICS
Preanalytical Systems		$	150,569			$	143,930				4.6				4.0				0.6
Diagnostic Systems			142,302				141,339				0.7				(0.3	)			1.0
TOTAL		$	292,871			$	285,269				2.7				1.9				0.8
BD BIOSCIENCES
Cell Analysis		$	160,487			$	153,731				4.4				4.6				(0.2	)
Discovery Labware			39,025				38,305				1.9				(0.1	)			2.0
TOTAL		$	199,512			$	192,036				3.9				3.6				0.3
TOTAL INTERNATIONAL		$	1,013,403			$	1,015,401				(0.2	)			(0.3	)			0.1

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended December 31, (continued)
(Unaudited; Amounts in thousands)

		Total
										% Change
		2010				2009				Reported				FXN				FX Impact
BD MEDICAL
Medical Surgical Systems		$	512,728			$	533,177				(3.8	)			(4.7	)			0.9
Diabetes Care			213,882				201,521				6.1				6.1				—
Pharmaceutical Systems			199,937				235,974				(15.3	)			(12.4	)			(2.9	)
TOTAL		$	926,547			$	970,672				(4.5	)			(4.3	)			(0.2	)
BD DIAGNOSTICS
Preanalytical Systems		$	312,628			$	300,166				4.2				3.9				0.3
Diagnostic Systems			289,094				295,308				(2.1	)			(2.6	)			0.5
TOTAL		$	601,722			$	595,474				1.0				0.6				0.4
BD BIOSCIENCES
Cell Analysis		$	240,742			$	231,335				4.1				4.2				(0.1	)
Discovery Labware			72,994				71,337				2.3				1.2				1.1
TOTAL		$	313,736			$	302,672				3.7				3.5				0.2
TOTAL REVENUES		$	1,842,005			$	1,868,818				(1.4	)			(1.5	)			0.1

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
SAFETY REVENUES
(Unaudited; Amounts in thousands)

		Three Months Ended December 31,
										% Change
		2010				2009				Reported				FXN				FX Impact
TOTAL SAFETY REVENUES
United States		$	283,782			$	291,815				(2.8	)			(2.8	)			—
International			169,254				155,129				9.1				7.5				1.6
TOTAL		$	453,036			$	446,944				1.4				0.9				0.5
BY SEGMENT
BD Medical		$	213,309			$	221,174				(3.6	)			(4.3	)			0.7
BD Diagnostics			239,727				225,770				6.2				5.8				0.4
TOTAL		$	453,036			$	446,944				1.4				0.9				0.5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS FISCAL 2010
Revised for discontinued operations of certain Medical segment divestitures
(Unaudited; Amounts in thousands)

		United States
		Quarter 1				Quarter 2				Quarter 3				Quarter 4				Year
BD MEDICAL
Medical Surgical Systems		$	273,991			$	237,174			$	239,866			$	256,290			$	1,007,322
Diabetes Care			96,564				92,515				96,071				98,633				383,783
Pharmaceutical Systems			62,021				52,078				45,824				45,308				205,231
TOTAL		$	432,576			$	381,767			$	381,761			$	400,231			$	1,596,336
BD DIAGNOSTICS
Preanalytical Systems		$	156,236			$	149,932			$	159,228			$	162,024			$	627,421
Diagnostic Systems			153,969				142,909				144,293				145,697				586,867
TOTAL		$	310,205			$	292,841			$	303,521			$	307,721			$	1,214,288
BD BIOSCIENCES
Cell Analysis		$	77,604			$	78,183			$	84,365			$	86,765			$	326,916
Discovery Labware			33,032				38,968				39,781				37,244				149,025
TOTAL		$	110,636			$	117,151			$	124,146			$	124,009			$	475,941
TOTAL UNITED STATES		$	853,417			$	791,759			$	809,428			$	831,961			$	3,286,565

		International
		Quarter 1				Quarter 2				Quarter 3				Quarter 4				Year
BD MEDICAL
Medical Surgical Systems		$	259,186			$	244,090			$	253,687			$	245,724			$	1,002,687
Diabetes Care			104,957				95,471				101,081				100,468				401,976
Pharmaceutical Systems			173,953				200,305				208,993				212,182				795,433
TOTAL		$	538,096			$	539,866			$	563,761			$	558,374			$	2,200,096
BD DIAGNOSTICS
Preanalytical Systems		$	143,930			$	137,738			$	144,298			$	144,421			$	570,386
Diagnostic Systems			141,339				125,093				128,450				139,322				534,205
TOTAL		$	285,269			$	262,831			$	272,748			$	283,743			$	1,104,591
BD BIOSCIENCES
Cell Analysis		$	153,731			$	164,292			$	146,068			$	160,230			$	624,322
Discovery Labware			38,305				40,661				38,906				38,887				156,759
TOTAL		$	192,036			$	204,953			$	184,974			$	199,117			$	781,081
TOTAL INTERNATIONAL		$	1,015,401			$	1,007,650			$	1,021,483			$	1,041,234			$	4,085,768

		Total
		Quarter 1				Quarter 2				Quarter 3				Quarter 4				Year
BD MEDICAL
Medical Surgical Systems		$	533,177			$	481,264			$	493,553			$	502,014			$	2,010,009
Diabetes Care			201,521				187,986				197,152				199,101				785,759
Pharmaceutical Systems			235,974				252,383				254,817				257,490				1,000,664
TOTAL		$	970,672			$	921,633			$	945,522			$	958,605			$	3,796,432
BD DIAGNOSTICS
Preanalytical Systems		$	300,166			$	287,670			$	303,526			$	306,445			$	1,197,807
Diagnostic Systems			295,308				268,002				272,743				285,019				1,121,072
TOTAL		$	595,474			$	555,672			$	576,269			$	591,464			$	2,318,879
BD BIOSCIENCES
Cell Analysis		$	231,335			$	242,475			$	230,433			$	246,995			$	951,238
Discovery Labware			71,337				79,629				78,687				76,131				305,784
TOTAL		$	302,672			$	322,104			$	309,120			$	323,126			$	1,257,022
TOTAL REVENUES		$	1,868,818			$	1,799,409			$	1,830,911			$	1,873,195			$	7,372,333

Certain quarterly amounts may not add to the year-to-date totals due to rounding.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS FISCAL 2009
Revised for discontinued operations of certain Medical segment divestitures
(Unaudited; Amounts in thousands)

		United States
		Quarter 1				Quarter 2				Quarter 3				Quarter 4				Year
BD MEDICAL
Medical Surgical Systems		$	244,037			$	231,041			$	244,077			$	255,168			$	974,324
Diabetes Care			88,465				83,233				91,330				88,590				351,618
Pharmaceutical Systems			42,652				43,065				43,460				48,353				177,529
TOTAL		$	375,154			$	357,339			$	378,867			$	392,111			$	1,503,471
BD DIAGNOSTICS
Preanalytical Systems		$	149,230			$	147,436			$	155,760			$	156,328			$	608,754
Diagnostic Systems			138,338				137,677				143,614				149,160				568,789
TOTAL		$	287,568			$	285,113			$	299,374			$	305,488			$	1,177,543
BD BIOSCIENCES
Cell Analysis		$	77,379			$	71,770			$	70,518			$	84,179			$	303,846
Discovery Labware			36,372				32,269				37,618				39,046				145,305
TOTAL		$	113,751			$	104,039			$	108,136			$	123,225			$	449,151
TOTAL UNITED STATES		$	776,473			$	746,491			$	786,377			$	820,824			$	3,130,165

		International
		Quarter 1				Quarter 2				Quarter 3				Quarter 4				Year
BD MEDICAL
Medical Surgical Systems		$	211,595			$	219,079			$	230,934			$	253,384			$	914,990
Diabetes Care			91,541				85,159				94,521				92,098				363,319
Pharmaceutical Systems			152,129				178,085				220,503				224,195				774,914
TOTAL		$	455,265			$	482,323			$	545,958			$	569,677			$	2,053,223
BD DIAGNOSTICS
Preanalytical Systems		$	128,924			$	131,029			$	136,427			$	138,297			$	534,677
Diagnostic Systems			123,699				123,498				130,578				136,224				513,999
TOTAL		$	252,623			$	254,527			$	267,005			$	274,521			$	1,048,676
BD BIOSCIENCES
Cell Analysis		$	152,142			$	159,223			$	139,251			$	150,055			$	600,671
Discovery Labware			36,645				40,578				37,818				38,946				153,987
TOTAL		$	188,787			$	199,801			$	177,069			$	189,001			$	754,658
TOTAL INTERNATIONAL		$	896,675			$	936,651			$	990,032			$	1,033,199			$	3,856,557

		Total
		Quarter 1				Quarter 2				Quarter 3				Quarter 4				Year
BD MEDICAL
Medical Surgical Systems		$	455,632			$	450,120			$	475,011			$	508,552			$	1,889,314
Diabetes Care			180,006				168,392				185,851				180,688				714,937
Pharmaceutical Systems			194,781				221,150				263,963				272,548				952,443
TOTAL		$	830,419			$	839,662			$	924,825			$	961,788			$	3,556,694
BD DIAGNOSTICS
Preanalytical Systems		$	278,154			$	278,465			$	292,187			$	294,625			$	1,143,431
Diagnostic Systems			262,037				261,175				274,192				285,384				1,082,788
TOTAL		$	540,191			$	539,640			$	566,379			$	580,009			$	2,226,219
BD BIOSCIENCES
Cell Analysis		$	229,521			$	230,993			$	209,769			$	234,234			$	904,517
Discovery Labware			73,017				72,847				75,436				77,992				299,292
TOTAL		$	302,538			$	303,840			$	285,205			$	312,226			$	1,203,809
TOTAL REVENUES		$	1,673,148			$	1,683,142			$	1,776,409			$	1,854,023			$	6,986,722

Certain quarterly amounts may not add to the year-to-date totals due to rounding.